0639 GMT - Fresenius Medical Care's results should see a positive share-price response on a higher net profit and sales and earnings that topped views, Morgan Stanley analysts say in a note. The German dialysis company's sales and earnings beat was driven by higher demand for is care enablement segment and cost discipline, they say. The company's reiterated full-year outlook for revenue and operating profit and a stable U.S. market treatment growth is a positive, they add. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
May 06, 2025 02:42 ET (06:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.